European journal of rheumatology and inflammation最新文献_第6页

The long-term U.S. study--a report on outcome and tolerance. 美国的一项长期研究——一份关于结果和耐受性的报告。

European journal of rheumatology and inflammation Pub Date : 1991-01-01

R Fleischmann

引用次数: 0

European journal of rheumatology and inflammation Pub Date : 1991-01-01

I Stroehmann

{"title":"A rheumatologist's viewpoint.","authors":"I Stroehmann","doi":"","DOIUrl":"","url":null,"abstract":"Attitudes to prescribing anti-inflammatory drugs have changed considerably over the last 25 years and there is now a recognition of the need to balance effectiveness with reduced risks of serious adverse reactions. Such serious side-effects often involve the upper gastrointestinal tract, and there are differences between anti-inflammatory drugs in the frequency with which they cause significant problems at this site. Anti-inflammatory drugs with a lesser propensity to cause gastrointestinal reactions may have an advantage. Several risk factors may be important for upper gastrointestinal side-effects including sex, age, history of dyspepsia, other diseases and the type of arthritis. Results from post-marketing surveillance studies of nabumetone in the United Kingdom and the Federal Republic of Germany showed that although patients with a previous history of dyspepsia were more likely to stop the drug due to an adverse reaction, the majority continued without any problem. Interestingly, patients with rheumatoid arthritis were more likely to stop therapy due to side-effects, though it was not clear if this was due to their disease or to multi-morbidity. Strategies are needed when prescribing anti-inflammatory drugs which take into account the type of patient, their disease, and the best drug. In many instances this could be nabumetone.","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"11 3","pages":"7-11"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12537686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A pharmacokinetic study to evaluate the profile of droxicam in elderly healthy volunteers after a single oral dose of 20mg. 老年健康志愿者单次口服20mg羟西康的药代动力学研究

European journal of rheumatology and inflammation Pub Date : 1991-01-01

J Hosie, J Kelly, J Sánchez, A Bartlett, F J Harrison

{"title":"A pharmacokinetic study to evaluate the profile of droxicam in elderly healthy volunteers after a single oral dose of 20mg.","authors":"J Hosie, J Kelly, J Sánchez, A Bartlett, F J Harrison","doi":"","DOIUrl":"","url":null,"abstract":"A single oral dose pharmacokinetic study in a group of 10 elderly healthy volunteers was performed to evaluate the pharmacokinetic profile and the potential effect of age on the absorption, distribution and elimination of droxicam. After complete medical screening, and informed written consent, one dose (20mg) of droxicam was administered to all volunteers, under medical supervision. A complete pharmacokinetic profile of the obtained blood plasma levels was evaluated over 120 hours. All volunteers completed the study and in none did droxicam cause intolerance or side effects. The results showed that droxicam absorption, distribution and elimination did not differ substantially from reference studies done with young healthy volunteers. The peak mean plasma concentration was at 10 hours 1.38 +/- 0.29 microgram/ml, declining slowly, reaching 0.24 +/- 0.20 microgram/ml at 120 hours, with a half life of 50.23 +/- 17.19 hours and an elimination rate constant of 0.015 +/- 0.005 microgram/ml.h-1. In comparison to the healthy, young volunteers, the variation was minimal. It can be concluded from this study that age causes minimal variations in the absorption and distribution of droxicam.","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"11 4","pages":"45-9"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12539352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The science--equivalent efficacy and diminished risk. 科学证明——同等功效和降低风险。

European journal of rheumatology and inflammation Pub Date : 1991-01-01

P Blower

引用次数: 0

Drug effects on a novel in vitro model of cartilage breakdown. 药物对新型软骨破裂体外模型的影响。

European journal of rheumatology and inflammation Pub Date : 1991-01-01

M el-Ghazaly, P Braquet, A Moore, D A Willoughby

引用次数: 0

Pharmacokinetic profile of droxicam. 氯昔康的药动学特征。

European journal of rheumatology and inflammation Pub Date : 1991-01-01

L Martínez, J Sánchez

{"title":"Pharmacokinetic profile of droxicam.","authors":"L Martínez, J Sánchez","doi":"","DOIUrl":"","url":null,"abstract":"Droxicam is a new non-steroid anti-inflammatory drug that is a pro-drug of piroxicam. The pharmacokinetics of droxicam, both as a single 10mg dose and as a multidose regimen of 10 and 20mg/day for 20 consecutive days, have been studied in healthy volunteers. Since transformation into piroxicam takes place in the gastrointestinal tract, unchanged droxicam was not detected in plasma. After a single 10mg dose the value of Tmax was higher than that reported for piroxicam (10mg). This effect is a consequence of the process of transformation of droxicam into piroxicam. The remaining pharmacokinetical parameters studied were similar to those reported in other studies on piroxicam (10mg). After multiple oral administration at a dose of 10 and 20mg/day, absorption kinetics of droxicam were delayed with respect to those of piroxicam. The other pharmacokinetical parameters studied showed no statistically significant differences between droxicam and piroxicam. Absorption and elimination of droxicam are independent of the administered dose and the bioavailability of droxicam and piroxicam was equal. The influence of gastric emptying on droxicam pharmacokinetics and bioavailability has been investigated in healthy volunteers. Gastric emptying was experimentally modified by use of propantheline and metoclopramide. Following modification of gastric emptying, only Tmax underwent significant increase (P < 0.05). Absorption rate of droxicam was modified but elimination and bioavailability did not suffer modification in conditions of altered gastric emptying.","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"11 4","pages":"10-4"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12537688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A double blind, placebo controlled study of niflumic acid gel in the treatment of acute tendinitis. 尼氟酸凝胶治疗急性肌腱炎的双盲、安慰剂对照研究。

European journal of rheumatology and inflammation Pub Date : 1991-01-01

R L Dreiser, A Ditisheim, J Charlot, A Lopez

{"title":"A double blind, placebo controlled study of niflumic acid gel in the treatment of acute tendinitis.","authors":"R L Dreiser, A Ditisheim, J Charlot, A Lopez","doi":"","DOIUrl":"","url":null,"abstract":"Percutaneously administered niflumic acid gel (Niflugel R, Laboratories UPSA, Rueil Malmaison, France) was compared to placebo in a double blind, placebo controlled, multicentre study in the treatment of acute upper and lower limb tendinitis. Fifty nine subjects were enrolled in three centres and were randomly allocated to receive treatment with 2.5% percutaneous niflumic acid gel or placebo gel applied three times daily for 7 days. Clinical evaluations were carried out on inclusion and after seven days of treatment. The variables measured were pain felt by the patient and the investigators' and patients' overall evaluation of the treatments' efficacy. The patients also kept a daily record of pain scores. Any adverse events that occurred were noted. The results showed that niflumic acid gel was significantly better than placebo in improving patient signs as regards overall efficacy ratings. Global evaluation of efficacy rated by the investigator showed that 25/29 patients (86.2%) were healed or improved in the niflumic acid gel group compared with 11/27 patients (40.7%) on placebo, p = < 0.01. The overall assessment of tolerance showed no difference between groups. Only two minor adverse effects were reported in patients treated with niflumic acid gel, and they did not require patients to stop treatment. The study findings indicate that treatment with topical niflumic acid gel is effective in the treatment of tendinitis and results in improved clinical signs at the end of 7 days.","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"11 2","pages":"38-45"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12538627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative double-blind study of droxicam (new NSAID) versus indomethacin in rheumatoid arthritis. droxicam(新型非甾体抗炎药)与吲哚美辛治疗类风湿关节炎的双盲比较研究。

European journal of rheumatology and inflammation Pub Date : 1991-01-01

A Rodríguez-de-la-Serna, C Geli-Ferrer, C Diaz-López, J Sánchez-García

{"title":"Comparative double-blind study of droxicam (new NSAID) versus indomethacin in rheumatoid arthritis.","authors":"A Rodríguez-de-la-Serna, C Geli-Ferrer, C Diaz-López, J Sánchez-García","doi":"","DOIUrl":"","url":null,"abstract":"This randomized, controlled and double-blind clinical trial compares the efficacy of droxicam (20mg/day) with that of indomethacin (75mg/day) in 40 RA patients (11 male, 29 female) aged (+/- SD) 53 +/- 12.5 years. After a 7-day single-blind run-in placebo period, patients were divided into two groups and treated for 9 weeks. Assessments were done at baseline and at the end of the 1st, 2nd, 4th, 6th and 9th weeks. Both drugs improved significantly the articular pain, the duration of morning stiffness, the articular index, the functional status and the degree of fatigue. Patient's and doctor's opinions were in accordance with the above-mentioned results. The effect of both drugs was more noticeable in the first 2 weeks of treatment. Droxicam was found to be statistically more active than indomethacin in alleviating morning stiffness and improving the functional status. The improvement of the variables induced by droxicam increased progressively throughout the study whereas that induced by indomethacin remained unchanged after the 2nd or 4th week of treatment. One patient treated with indomethacin withdrew from the study due to staggering and dizziness and several patients reported dyspepsia. Droxicam seems to be as effective as indomethacin (75mg/day) in the symptomatic relief of RA patients. The possibility of the use of droxicam for the relief of morning stiffness is of particular interest.","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"11 4","pages":"35-44"},"PeriodicalIF":0.0,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12539351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

NSAIDs for the new decade--nabumetone? 新十年的非甾体抗炎药——萘美酮?

European journal of rheumatology and inflammation Pub Date : 1991-01-01

E C Huskisson

引用次数: 0

The epidemiology of NSAID associated gastrointestinal disease. 非甾体抗炎药相关胃肠道疾病的流行病学研究。

European journal of rheumatology and inflammation Pub Date : 1991-01-01

F Wolfe

引用次数: 0